Atrial fibrillation and thromboprophylaxis in heart failure: The need for patient-centered approaches to address adherence

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 3-11

  Ferguson, Caleb ^a   Inglis, Sally C ^a   Newton, Phillip J ^a   Middleton, Sandy ^b,c   Macdonald, Peter S ^c,d   Davidson, Patricia M ^a,c  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anticoagulation; Atrial fibrillation; Heart failure; Medication adherence; Risk stratification; Stroke risk

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ALCOHOL CONSUMPTION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DIET RESTRICTION; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; FALL RISK ASSESSMENT; FRAIL ELDERLY; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MEDICAL ASSESSMENT; MEDICAL AUDIT; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SELF MONITORING; THROMBOSIS PREVENTION;

ANTICOAGULATION; ATRIAL FIBRILLATION; HEART FAILURE; MEDICATION ADHERENCE; RISK STRATIFICATION; STROKE RISK;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HEART FAILURE; HUMANS; MEDICATION ADHERENCE; PATIENT-CENTERED CARE; RISK ASSESSMENT; STROKE;

EID: 84873858912     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S39571     Document Type: Review

References (82)

1. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ. 2011 Update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust. 2011;194(8):405-409.
2. Gheorghiade M, Filippatos G. Reassessing treatment of acute heart failure syndromes: the ADHERE Registry. Eur Heart J Suppl. 2005;7(Suppl B):B13-B19.
3. Pullicino P, Homma S. Stroke in heart failure: atrial fibrillation revisited? J Stroke Cerebrovasc Dis. 2010;19(1):1-2.
4. Atrial fibrillation [webpage on the Internet]. Atrial fibrillation (CG36): the management of atrial fibrillation. National Institute for Health and Clinical Excellence; 2006 [updated July 10, 2012]. Available from: http://www.nice.org.uk/cg36. Accessed December 17, 2012.
5. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123(1):104-123.
6. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;114(7): e257-e354.
7. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638-645.
8. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th ed. Chest. 2008;133(Suppl 6): 546S-592S.
9. Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke. 2008;39(1):227-230.
10. Baczek VTL, Chen WT, Kluger J, Coleman CI. Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract. 2012;13(1):5.
11. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.
12. Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of fraility on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009;38(2):156-162.
13. Lip GY. Implications of the CHA2DS2-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation. Am J Med. 2011;124(2): 111-114.
14. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493-503.
15. Homma S, Thompson JLP, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. New Engl J Med. Epub May 2, 2012.
16. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290(8):1049-1056.
17. Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123(6):484-488.
18. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.
19. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 1999;30(6):1223-1229.
20. Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke. 2007;38(9):2459-2463.
21. Boriani G, Botto GL, Padeletti L, et al. Improving stroke risk stratification using the CHADS2 and CHA2DS2VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke. 2011;42(6):1768-1770.
22. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713-719.
23. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/ Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-180.
24. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35(10):2362-2367.
25. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105(2):91-99.
26. Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159(5):457-460.
27. Komajda M, Lapuerta P, Hermans N, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J. 2005;26(16):1653-1659.
28. World Health Organization. Adherence to Long Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003. Available from: http://whqlibdoc.who.int/publications/2003/9241545992.pdf. Accessed December 17, 2012.
29. Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009;54(14):1280-1289.
30. Nieuwlaat R, Eurlings LW, Cleland JG, et al. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol. 2009;53(18):1690-1698.
31. Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost. 2011;9(Suppl 1):S344-S351.
32. Go AS. Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care. 2004;10(Suppl 3):S58-S65.
33. Ezekowitz M, Bridgers SL, James KE, et al. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. New Engl J Med. 1992;327(20):1406-1412.
34. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13): 1449-1457.
35. Stroke Prevention In Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation trial. Final results. Circulation. 1991;84(2):527-539.
36. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110(3):453-460.
37. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med. 2012; 172(8):623-631.
38. Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: implications for thrombophrophylaxis. J Am Coll Cardiol. 2010;56(11):827-837.
39. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(6):624-631.
40. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125(19):2298-2307.
41. Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Management of warfarin in atrial fibrillation: views of health professionals, older patienst and their carers. Med J Aust. 2007;186(4):175-180.
42. Bo S, Valpreda S, Scaglione L, et al. Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study. BMC Public Health. 2007;7(1):203.
43. Brophy MT, Snyder KE, Gaehde S, Ives C, Gagnon D, Fiore LD. Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc. 2004;52(7):1151-1156.
44. Srivastava A, Hudson M, Hamoud I, Cavalcante J, Pai C, Kaatz S. Examining warfarin underutilization rates in patients with atrial fibrillation: detailed chart review essential to capture contraindications to warfarin therapy. Thromb J. 2008;6:6.
45. Tulner LR, Van Campen JP, Kuper IM, et al. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation. Drugs Aging. 2010;27(1):39-50.
46. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993; 342(8883):1317-1322.
47. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458-1465.
48. Rewiuk K, Wizner B, Fedyk-Lukasik M, et al. Heart failure and atrial fibrillation does practice meet the anticoagulation guidelines? Int J Cardiol. 2012;157(2):274-275.
49. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th ed. Chest. 2008;133(6 Suppl):160S-198S.
50. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18(2):349-355.
51. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293(6):690-698.
52. Stroke Prevention In Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348(9028):633-638.
53. Appelboam R, Thomas EO. Warfarin and intracranial haemmorhage. Blood Rev. 2009;23(1):1-9.
54. Sjoblom L, Hardemark HG, Lindgren A, et al. Management and prognostic features of intracerebral hemmorhage during anticoagulant therapy: a Swedish multicenter study. Stroke. 2001;32(11):2567-2574.
55. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011; 365(11):981-992.
56. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011;365(10):883-891.
57. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009;361(12): 1139-1151.
58. Battinelli EM. Reversal of new oral anticoagulants. Circulation. 2011;124(14):1508-1510.
59. Mussigbrodt A, Hindricks G. Clinical implications from recent trials and new guidelines for stroke prevention in atrial fibrillation. Eur Cardiol. 2012;8(3):174-178.
60. Horstkotte D, Piper C. Improvement of oral anticoagulation therapy by INR self-management. J Heart Valve Dis. 2004;13(3):335-338.
61. Giuffrida A, Torgerson D. Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ. 1997;315(7110): 703-707.
62. Ali A, Bailey C, Abdelhafiz AH. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis. Age Ageing. 2012;41(5):681-684.
63. Dunlay SM, Eveleth JM, Shah ND, McNallan SM, Roger VL. Medication adherence among community-dwelling patients with heart failure. Mayo Clin Proc. 2011;86(4):273-281.
64. Dolor RJ, Ruybalid RL, Uyeda L, et al. An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481 The Home INR Study (THINRS). J Thromb Thrombolysis. 2010;30(3):263-275.
65. Wu JR, Moser DK, Chung ML, Lennie TA. Predictors of medication adherence using a multidimensional adherence model in patients with heart failure. J Card Fail. 2008;14(7):603-614.
66. Brown SB, Shannon RP. Improving medication compliance in patients with heart failure. Am J Cardiol. 2008;101(2):274-277.
67. van der Wal MH, Jaarsma T. Adherence in heart failure in the elderly: problem and possible solutions. Int J Cardiol. 2008;125(2):203-208.
68. De Smedt RH, Denig P, van der Meer K, Haaijer-Ruskamp FM, Jaarsma T. Self-reported adverse drug events and the role of illness perception and medication beliefs in ambulatory heart failure patients: a cross-sectional survey. Int J Nurs Stud. 2011;48(12):1540-1550.
69. NEHI. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease. Cambridge, MA: NEHI; 2009. Available from: http://www.nehi.net/publications/44/thinking_outside_the_pillbox_a_systemwide_approach_to_improvingpatient_medication_adherence_for_chronic_disease. Accessed December 6, 2012.
70. McCabe PJ, Schumacher K, Barnason SA. Living with atrial fibrillation: a qualitative study. J Cardiovasc Nurs. 2011;26(4):336-344.
71. Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc. 2005;53(11):1912-1920.
72. Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients' warfarin knowledge and anticoagulation control. Ann Pharmacother. 2003;37(1):34-39.
73. Inglis SC, Cark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010;8:CD007228.
74. Robert-Ebadi H, Le Gal G, Righini M. Use of anticogulants in elderly patients: practical recommendations. Clin Interv Aging. 2009;4: 165-177.
75. Sansossian S, Ovbiagele B. Prevention and management of stroke in very elderly patients. Lancet Neurol. 2009;8(11):1031-1041.
76. Krass I, Ogle SJ, Duguid MJ, Shenfield GM, Bajorek BV. The impact of age on antithrombotic use in elderly patients with non-valvular atrial fibrillation. Australas J Ageing. 2002;21(1):36-41.
77. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med. 2005;165(21):2508-2513.
78. Walker GA, Heidenreich PA, Phibbs CS, et al. Mental illness and warfarin use in atrial fibrillation. Am J Manag Care. 2011;17(9):617-624.
79. Vaccarino V, Kasl SV, Abramson J, Krumholz HM. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol. 2001;38(1):199-205.
80. Forman DE, Rich MW, Alexander KP, et al. Cardiac care for older adults. Time for a new paradigm. J Am Coll Cardiol. 2011;57(18): 1801-1810.
81. Flaker GC, Pogue J, Yusuf S, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(3):277-283.
82. Hauptman PJ. Medication adherence in heart failure. Heart Fail Rev. 2008;13(1):99-106.